US Pharma MarketingAccording to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.
Abivax shares surge as worries subside over immune drug’s cancer risk
According to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.
Source: BioPharma Dive